Development of Retinoic Acid Formulation for Acne
- Conditions
- Acne vulgarisL60-L75C17.800.030.150Disorders of skin appendages
- Registration Number
- RBR-3t5ts4
- Lead Sponsor
- Faculdade de Farmácia da Universidade Federal de Minas Gerais
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruitment completed
- Sex
- Not specified
- Target Recruitment
- Not specified
Healthy volunteers; both genders; age between 18 and 35 years
Present hypersensitivity to any of the components of the formulation; pregnant women; lactating; have skin burns, eczema or any other chronic skin disease; atopic individuals; present any metabolic disease; have any autoimmune disease; having had a vaccine up to two weeks before the start of the study or having the intention to have a vaccine while the study was being conducted; having already undergone chemotherapy treatment or being undergoing this type of treatment; making use of corticosteroid medications; make use of potentially photosensitizing drugs, such as thiazides, tetracyclines, fluoroquinolones, phenothiazines and sulfonamides during the conduct of the experiment; individuals who are exposed to the intense sun frequently or who have been exposed to the intense sun in the last four months; individuals whose forearm skin has undergone procedures such as hair removal, chemical peels, dermabrasion or laser resurfacing.
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Decrease in skin toxicity promoted by topical application of retinoic acid carried in formulations of nanostructured lipid carriers (NLC) and solid lipid nanoparticles (SLN) when compared to the conventional formulation of commercially available retinoic acid (Vitanol®, Stiefel), verified by the reduction of transepidermal water loss, based on a statistically significant finding with a 95% confidence interval.
- Secondary Outcome Measures
Name Time Method Secondary outcomes are not expected